Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a fully integrated, late-stage biotechnology and genetic medicine company. The firm designs, develops, and commercializes innovative, multi-platform investigational gene therapies aimed at correcting the root causes of severe, rare, and devastating monogenic cardiac and hematologic disorders.